Vinpocetine and dementia
What 2 graded rows on vinpocetine agree on for dementia, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Vinpocetine page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Vinpocetine page, with its PubMed record.
Your question
Vinpocetine and dementia
2 rows · 786 peopleSplit. 1 row found an improvement and 1 had mixed results.
- CGrade C× 2
- Rows
- 2
- Trials
- 4
- People
- 786
- Pooled reviews may count some twice
What the rows share
From the rowsThe best-graded row, grade C, is a meta-analysis of 583 people (2003) and reported mixed results.
The rows run from 203 to 583 people, published from 1991 to 2003: 1 pooled review and 1 single study.
The rows
1 improved · 1 mixed- CGrade CGlobal improvement and cognitive performance in mild-to-moderate organic psychosyndromes · Improved
RCT · n 203 · 1991 · Outpatients with mild to moderate organic psychosyndromes, including primary dementia
3 × 10 mg or 3 × 20 mg per day (30 or 60 mg/day) · 16 weeks
Both doses beat placebo on clinical global improvement and a cognitive test (SKT); the higher dose was not better than the lower one. Adverse events were similar to placebo.
- CGrade CCognition and global impression in dementia · Mixed
Meta-analysis, 3 studies · n 583 · 2003 · People with vascular, Alzheimer’s or mixed dementia (3 trials, all run before the 1990s)
30 mg/day and 60 mg/day · Up to 1 year (few people treated for 6 months or more)
Benefits over placebo were reported, but few people were treated for 6 months or longer and intention-to-treat data were missing; reviewers judged the evidence inconclusive and not supportive of clinical use.
Row on the Vinpocetine page · PubMed 12535455 (opens PubMed)